Literature DB >> 15779865

The change of intracellular pH is involved in the cisplatin-resistance of human lung adenocarcinoma A549/DDP cells.

Zhenhua Huang1, Youguo Huang.   

Abstract

We had reported that the intracellular pH (pHi) of human lung adenocarcinoma A549 cells, which is sensitive to cisplatin, was more acidic than that of cisplatin-resistant A549/DDP cells. The correlation between the change of the pHi and cisplatin-resistance of A549/DDP cells was further studied by altering pHi in consequence of the change of CO2 concentration of the incubator. The pHi alterations of the cells were monitored by using the fluorescence probe of BCECF-AM. The results indicated that the pHi was more alkaline at lower CO2 concentration (2% CO2 in the incubator) and more acidic at higher CO2 concentration (8% CO2 in the incubator) for both A549 and A549/DDP cells compared with those of both A549 and A549/DDP cells cultured at 5% CO2 as the normal condition. Accumulation of bodipy-cisplatin, a fluorescence probe used for drug resistance assays, in A549 cells incubated at 2%, 5%, and 8% CO2 was increased 8.4%, 17.4%, and 23.5% compared to A549/DDP cells, respectively. Intracellular sequestration and distribution of bodipy-cisplatin imaged by laser scanning confocal microscopy indicated that bodipy-cisplatin was more encapsulated in acidic compartments of A549/DDP cells as shown with acridine orange, a dye that specifically labels acidic organelles in the cells. These results can be further confirmed in liposome systems with different pH gradients. It is proposed from the above results that the change of pHi in especially more acidic compartments in A549/DDP cells involves their cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15779865

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

Review 2.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

3.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

Review 4.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

5.  Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo.

Authors:  Marina V Shirmanova; Irina N Druzhkova; Maria M Lukina; Varvara V Dudenkova; Nadezhda I Ignatova; Ludmila B Snopova; Vladislav I Shcheslavskiy; Vsevolod V Belousov; Elena V Zagaynova
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

6.  In vivo visualization of the i-motif DNA secondary structure in the Bombyx mori testis.

Authors:  Wenhuan Tang; Kangkang Niu; Guoxing Yu; Ying Jin; Xian Zhang; Yuling Peng; Shuna Chen; Huimin Deng; Sheng Li; Jian Wang; Qisheng Song; Qili Feng
Journal:  Epigenetics Chromatin       Date:  2020-03-05       Impact factor: 4.954

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.